key: cord-0031338-maqo1vtq
authors: Singh, Rhea; Ali, Rowanne; Prasad, Sonya; Chen, Steven T.; Blumenthal, Kimberly; Freeman, Esther E.
title: Proposing a Standardized Assessment of COVID-19 Vaccine Cutaneous Reactions
date: 2022-05-13
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2022.05.011
sha: 949f77a049d05d43c15cb5e6f4128d812eb18de7
doc_id: 31338
cord_uid: maqo1vtq

nan

No standardized grading scale exists for the full spectrum of COVID-19 vaccine-induced 45 cutaneous reactions, and the time cut-off of what is potentially attributable to vaccination is unclear. Skin 46 reactions to prior vaccines have been characterized by severity scales that generally do not specify 47 cutaneous reactions to the vaccines. 1,2 COVID-19 vaccine clinical trials used the U.S. FDA's Toxicity 48 grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials 49 (FDA toxicity scale). 3 Only local injection site cutaneous reactions were categorized on this scale, with 50 little granularity to grading of specific dermatological conditions. This incomplete picture does not allow 51 for proper severity grading, assessment, and treatment of dermatology patients. 52

A Medline/PubMed database literature search of allergic reaction, drug reaction, and dermatologic 53 reaction severity grading scales published from January 2000 to December 2021 was conducted for 54 relevant literature utilizing the following MeSH terms: allergic reaction, severity grading scales, drug 55 reactions, vaccine reactions. The number of citations for each scale was identified and the ten most cited 56 scales for each type of reaction were evaluated. The search was subsequently expanded to include relevant 57 terminology based on initial searches; for example, "NCI Common Terminology Criteria for Adverse 58 Events (CTCAE)," "Ring and Messmer scale," and "Toxicity grading scale for healthy adult/adolescent 59 volunteers enrolled in preventive vaccine clinical trials" were included to encompass the most common 60 assessment instruments utilized/adapted for reaction severity grading. 4 Each grading system's relevancy 61 to grading COVID-19 vaccine cutaneous reactions was assessed using a standardized data extraction tool. 62

We reviewed 30 articles encompassing most cited allergic reaction scales, drug reaction scales, 63 dermatologic reaction scales, and vaccine characterization scales. Of these, the ten most relevant scales 64 were analyzed for consideration in the COVID-19 cutaneous vaccine reaction grading process. The FDA 65 toxicity scale contains relevant detail on local reactions, but lacked detail on other types of rashes seen 66 after vaccination. 3 The Brighton Collaboration criteria, Ring and Messmer scale, and NIAID/FAAN 67 J o u r n a l P r e -p r o o f criteria were appropriate for acute onset skin reactions and anaphylaxis; however, they were not useful for 68 describing delayed or chronic cutaneous reactions seen after vaccination. The scale capable of grading the 69 broadest spectrum of COVID vaccine skin reactions was the National Cancer Institute's Common 70

Terminology Criteria for Adverse Events (CTCAE) scale, which has been previously adapted for drug-71 induced cutaneous reactions. We therefore mapped known COVID-19 cutaneous vaccine reactions to 72 FDA's Toxicity scale (local reactions) and NCI's CTCAE scale (generalized reactions) ( Table 1 ,2). In 73 general, the CTCAE scale suggests a Grade 1 reaction is <10% BSA, Grade 2 is 10-30% BSA, and Grade 74 3 is >30% BSA. We suggest cutaneous reactions can be attributed to the COVID-19 vaccine only if the 75 first instance occurs within 21 days of vaccine administration, to align with prior data analysis of adverse 76 events by authors from the CDC's Immunization Safety Office. 5 77

Adoption of standardized terminology and grading for COVID-19 vaccine skin reactions will 78 assist researchers and clinicians in better characterizing vaccine reactions and providing appropriate 79 counseling for patients as vaccines against COVID-19 continue to be needed globally. 80 J o u r n a l P r e -p r o o f according to the FDA Toxicity Grading Scale* 82

Does not interfere with activity J o u r n a l P r e -p r o o f 

Macules/papules covering <10% BSA with or without symptoms (e.g., pruritus, burning, tightness)

Macules/papules covering 10 -30% BSA with or without symptoms (e.g., pruritus, burning, tightness); limiting instrumental ADL; rash covering > 30% BSA with or without mild symptoms Macules/papules covering >30% BSA with moderate or severe symptoms; limiting self-care ADL Hair loss of <50% of normal for that individual that is not obvious from a distance but only on close inspection; a different hair style may be required to cover the hair loss, but it does not require a wig or hair piece to camouflage

Hair loss of >=50% normal for that individual that is readily apparent to others; a wig or hair piece is necessary if the patient desires to completely camouflage the hair loss; associated with psychosocial impact J o u r n a l P r e -p r o o f Reactions" and "Bronchospasm" categories 124 † †Not explicitly present in CTCAE V5.0 and therefore this was adapted from the V5.0 "Eczema" and 125 "Dry Skin" categories 126 127

A post hoc analysis utilizing the FDA toxicity grading 129 scale to assess injection site adverse events following immunization with the live attenuated Zoster 130

Vaccine (ZVL)

A grading system for 132 local skin reactions developed for clinical trials of an intradermal and transcutaneous ETEC 133 vaccine

Adaptation of a previously validated vaccination report 135 card for use in adult vaccine clinical trials to align with the

Common Terminology Criteria for Adverse Events

Surveillance for Adverse Events After COVID-19 mRNA 140

†Immediate acute urticaria <24 hours; delayed acute urticaria < 6 weeks; chronic urticaria > 6 weeks. 104Scale presented in the table is from CTCAE V5.0. The CTCAE includes "topical intervention needed" 105 under grade 1; however, in order to align more closely with Allergy and Immunology guidelines, we have 106 removed this from our proposed grading system. Alternatively, a scale that is used by Allergy and 107Immunology is "The diagnosis and management of acute and chronic urticaria: 2014 update." Stage 1: 108Monotherapy with second generation antihistamine + avoidance of triggers. Stage 2: Add another second-109 generation antihistamine or H2 antagonist or leukotriene receptor antagonist + first-generation 110 antihistamine at bedtime. Stage 3: Dose advancement of potent antihistamine. Stage 4: Add omalizumab, 111 cyclosporine, anti-inflammatory, immunosuppressants, or biologics. 112 ǂ Not explicitly present in CTCAE V5.0 and therefore this was adapted from the V5.0 "Skin and 113 subcutaneous tissue disorders" generalized category 114 ¶ Not explicitly present in CTCAE V5.0 and therefore this was adapted from the V5.0 "Maculo-papular 115 rash" category 116 § Not present in CTCAE V5.0 and therefore this was adapted from the V5.0 "Lymphedema" and 117 "Vasculitis" categories 118 || Not explicitly present in CTCAE V5.0 and therefore this was adapted from the V5.0 "Palmar-plantar 119 erythrodysesthesia syndrome" category 120 # Not explicitly present in CTCAE V5.0 and therefore this was adapted from the V3.0 "Striae" cosmetic 121 reactions category 122 J o u r n a l P r e -p r o o f